金纳米壳用于前列腺癌治疗:腹部器官沉积的证据
单机构回顾性研究纳入4例接受金-硅纳米壳治疗的前列腺癌患者,对比治疗前后腹部平扫CT,发现肝脏平均增加28.9 HU(p=0.010)、脾脏平均增加63.7 HU(p=0.012),其余测量部位变化为-0.1至3.8 HU(p>0.05),结论认为肝脾CT衰减增高是金-硅纳米壳治疗后的预期表现。
要点
- 前列腺癌金-硅纳米壳治疗后,肝脏和脾脏CT平扫衰减可增高,属预期表现。
- 肝脏平均增加28.9 HU(p=0.010),脾脏平均增加63.7 HU(p=0.012)。
- 其余测量部位(胰腺、肾、前列腺、血池、椎旁肌肉等)变化为-0.1至3.8 HU(p>0.05)。
核心结论
- 金-硅纳米壳治疗后肝脏和脾脏CT衰减增高可以是预期表现。
研究设计与样本
- 单机构回顾性研究,纳入AuroLase先导试验中接受治疗前后腹部盆腔平扫CT的4例患者,由两名阅片者手动测量衰减,采用组内相关系数(ICC)评估阅片者间一致性,并用置换检验评估治疗前后衰减差异。
关键影像表现/征象
- 治疗前后器官衰减差异最大见于全部4例患者的肝脏和脾脏。
- 肝脏平均增加28.9 HU(p=0.010)。
- 脾脏平均增加63.7 HU(p=0.012)。
- 单个测量的淋巴结平均增加58.9 HU。
- 其余测量部位治疗前后衰减变化范围为-0.1至3.8 HU(p>0.05)。
诊断标准与关键数值
- 两名阅片者衰减测量一致性很高(ICC=0.99,p<0.001)。
临床应用与阅片要点
- 对于接受金-硅纳米壳治疗的患者,阅片时可将肝脏和脾脏CT衰减增高视为预期表现。
局限性
- 本研究为单机构回顾性研究。
- 仅4例患者符合纳入标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Gold-silica nanoshell therapy [AuroShells with subsequent focal laser therapy (AuroLase)] is an emerging targeted treatment modality for prostate cancer. We reviewed pre- and post-treatment unenhanced CT imaging to assess for retained gold-silica nanoshells in the abdomen and pelvis.
METHODS: This single-institution retrospective study identified patients in the AuroLase pilot who underwent pre- and post-treatment unenhanced abdominopelvic CT. The attenuation, before and after gold-silica nanoshell administration, of the liver, spleen, pancreas, kidneys, prostate, blood pool, paraspinal musculature, and abnormal lymph nodes were manually measured by two readers. After inter-reader agreement was calculated using intraclass correlation (ICC), a permutation test was used to assess pre- and post-therapy attenuation differences.
RESULTS: Four patients met the inclusion criteria. Mean age was 72.3 ± 5.9 years. Median time interval between pre-treatment CT and treatment, and between treatment and post-treatment CT, was 232 days and 236.5 days, respectively. The two readers' attenuation measurements had very high agreement (ICC = 0.99, p < 0.001). The highest differences in organ attenuation between pre- and post-therapy scans were seen in all four patients in the liver and spleen (liver increased by an average of 28.9 HU, p = 0.010; spleen increased by an average of 63.7 HU, p = 0.012). A single measured lymph node increased by an average of 58.9 HU. In the remainder of the measured sites, the change in attenuation from pre- to post-therapy scans ranged from -0.1 to 3.8 HU (p > 0.05).
CONCLUSION: Increased attenuation of liver and spleen at CT can be an expected finding in patients who have received gold-silica nanoshell therapy.
引用
- Gaur S, Stein EB, Schneider DK, et al. Gold nanoshells for prostate cancer treatment: evidence for deposition in abdominal organs. Abdom Radiol (NY). 2024. PMID: 38376575. doi:10.1007/s00261-024-04184-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。